Document is current
Any future updates will be listed below
-
Authors
Mohan, Nitesh https://orcid.org/0000-0001-6929-9504
Srivastava, Sunil K.
Duphare, Chandni
Gilligan, Timothy D.
Ali, Mir Yusuf https://orcid.org/0009-0009-2043-3413
Ornstein, Moshe C.
Sobecks, Ronald
Shepard, Dale
Sharma, Sumit https://orcid.org/0000-0001-5769-0717
- License Information
-
More Information
Article History
Received: 21 August 2025
Revised: 9 December 2025
Accepted: 6 January 2026
First Online: 6 February 2026
Competing interests
: NM, CD, TDG, MYA, RS: None SKS: Grants from Regeneron, Eyevensys, Eyepoint, and Gilead, and consulting fees from Adverum, Novartis, Zeiss, and Bausch and Lomb. MO: Consulting or advisory roles for Eisai, Exelixis, Pfizer, Aveo, Merck, Seattle Genetics, and Bristol Myers Squibb; served on speakers bureaus for Bristol Myers Squibb; received institutional research funding from Bristol Myers Squibb, Pfizer, Merck, Astra-Zeneca, HiberCell, Arcus. DS: Consulting fees from Bayer, Deciphera, and institutional research support from Deciphera, Novartis SS : Consulting fees from 4DMT, Alimera, Abbvie, Apellis, Astellas, Bausch and Lomb, Clearside, Eyepoint, Harrow, Genetech/Roche, Kodiak, Merck, Regeneron, RegenXBio, Ripple, Volk, and Zeiss with contracted research support from Acelyrin, Gilead, Genetech/Roche, Santen, IONIS, Kodiak
